CloudMD: Canaccord Raises Price Target To $3.75

Wednesday morning, it was announced that CloudMD Software & Services (TSXV: DOC) is acquiring VisionPros, a vertically integrated eyecare platform. The deal will cost CloudMD C$60 million along with a potential one-time C$40 million earnout. The C$60 million comes in one C$30 million cash payment and one C$30 million payment in common shares of the company. Following this, they also announced a C$45 million bought deal, which was upsized yesterday morning to C$55 million.

CloudMD currently has five analysts covering the company with a weighted 12-month price target of C$3.91. This is slightly up from the average in January, which was C$3.33. One analyst has a strong buy rating, while the other four analysts have buy ratings.

Canaccord’s Doug Taylor raised CloudMD’s 12-month price target to C$3.75 from C$3.25 while reiterating their speculative buy rating on the name. He writes, “Today’s announcement represents the single largest acquisition DOC has undertaken and brings the company’s annualized revenue run rate to over $85M.” He also believes that this deal could bring potential cross-selling opportunities for patients.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

In the news release, CloudMD noted that VisionPro had generated over C$22m in revenue with a >10% EBITDA margin during 2020. Taylor writes, “The deal is financially accretive, with upfront consideration representing 2.7x trailing revenue (4.5x including earnouts) vs. DOC 8.7x 2021E EV/Sales.” Taylor believes that gross margin is in-line with CloudMD’s of 30% and says that if the earnout were trigged by VisionPro growing 50% annually across 2021 and 2022, it would make Canaccord upgrade their forecast.

Alongside the potential cross-selling, Taylor believes the potential exists for synergies with CloudMD’s Rx Infinity digital pharmacy acquisition. Below you can see the key estimates that Canaccord has made for 2021 and 2022 for the firm.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

One Response

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

Argonaut Gold: Canaccord Slashes Target To $0.65 Following Dilutive Financing

On July 5, Argonaut Gold (TSX: AR) announced that they closed a C$195.3 million offering...

Thursday, July 7, 2022, 11:39:00 AM

Stifel Downgrades Aurora Cannabis Price Target To $3.60 Based On Liquidation Analysis

This morning, Stifel downgraded their 12-month price target on Aurora Cannabis (TSX: ACB) (NYSE: ACB)...

Wednesday, October 28, 2020, 10:59:00 AM

Equinox: BMO Lowers Price Target After Second Blockade In Nine Months

On June 22nd, Equinox Gold Corp. (TSX: EQX) announced that there has been illegal blockades set...

Thursday, June 24, 2021, 04:14:00 PM

BMO Reiterates Ratings On Eldorado Gold Despite Poor Quarterly Performance

Eldorado Gold (TSX: ELD) is down 8% since it reported its first-quarter financial results on...

Tuesday, May 3, 2022, 02:22:00 PM

Green Thumb: Analysts Upgrade Ratings On Back Of Earnings Beat

This morning Canaccord Genuity raised their 12-month price target on Green Thumb Industries (CSE: GTII)...

Thursday, November 12, 2020, 10:50:37 AM